The latest myeloma news
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine,…
A growing repertoire of cell and molecule-based immunotherapies is offering patients with indomitable cancers new…
The European Commission (EC) has granted the approval of a type II variation application for…
The US Food and Drug Administration (FDA) has given the green light to Elrexfio™ (elranatamab-bcmm),…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)…
Combining five existing drugs can keep a highly aggressive type of bone marrow cancer at…
A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights…
The Menarini Group (“Menarini”), announced important new data on selinexor at the European Hematology Association (EHA) Congress 2023.…
Ciltacabtagene autoleucel, a BCMA-targeting CAR T-cell therapy, significantly slows or stops progression of multiple myeloma…
Numerous studies have shown that people from racial and ethnic minority groups are underrepresented in…